Longeveron (LGVN) Cash from Financing Activities (2020 - 2026)

Longeveron (LGVN) recorded quarterly Cash from Financing Activities of $15.5 million in Q1 2026, up 1893.18% quarter-over-quarter from $777000.0 in Q4 2025, and up 26801.72% on a YoY basis from N/an in Q1 2025.

Longeveron (LGVN) Cash from Financing Activities (2020 - 2026) Analysis & Trends

Longeveron's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $15.5 million for Q1 2026.

  • In Q1 2026, Cash from Financing Activities rose 26801.72% year-over-year to $15.5 million; the TTM figure through Mar 2026 stood at $20.2 million (down 29.49% YoY), while the FY2025 annual figure was $4.7 million, down 83.78% from the prior year.
  • Cash from Financing Activities was $15.5 million for Q1 2026 at Longeveron, up from $777000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $15.5 million in Q1 2026 to a low of -$193000.0 in Q4 2022.
  • Historically, Cash from Financing Activities has averaged $3.2 million across 5 years, with a median of -$27000.0 in 2022.
  • The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities sank 678.95% in 2022, then soared 27548.0% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at -$193000.0 in 2022, then soared by 2905.7% to $5.4 million in 2023, then plunged by 100.92% to -$50000.0 in 2024, then surged by 1654.0% to $777000.0 in 2025, then soared by 1893.18% to $15.5 million in 2026.
  • The last three Cash from Financing Activities figures came in at $15.5 million (Q1 2026), $777000.0 (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 7.00 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -600,000.00
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - 53,000.00
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -538.80 Mn
9 Abivax 91.96 Bn 91.96 Bn - 85,464.43
10 Longeveron 20.35 Bn 20.33 Bn 264,000.00 15.49 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 15.49 Mn
Mar 31, 2026 15.49 Mn
Dec 31, 2025 777,000.00
Dec 31, 2025 777,000.00
Sep 30, 2025 4.08 Mn
Sep 30, 2025 4.08 Mn
Jun 30, 2025 -133,000.00
Jun 30, 2025 -133,000.00
Mar 31, 2025 -58,000.00
Mar 31, 2025 -58,000.00
Dec 31, 2024 -50,000.00
Dec 31, 2024 -50,000.00
Sep 30, 2024 13.72 Mn
Sep 30, 2024 13.72 Mn
Jun 30, 2024 15.05 Mn
Jun 30, 2024 15.05 Mn
Mar 31, 2024 63,000.00
Mar 31, 2024 63,000.00
Dec 31, 2023 5.42 Mn
Dec 31, 2023 5.42 Mn